Introduction:

In patients with resistant castration prostate cancer (RCPC), the TROPIC study established cabazitaxel 25 mg/ m2 as the standard second-line chemotherapy. In order to reduce the adverse effects, the PROSELICA study evaluated whether the decrease in the dose of cabazitaxel at 20 mg/m2 was not inferior fulfilling the objective. We propose this study to know the side effects of cabazitaxel in our population

Materials and Methods:

Patients > 18 years with RCPC, treated with cabazitaxel at a dose of 20 mg/m2 and 25 mg/m2, from 2014 to 2017, in a population of Centro Médico Nacional 20 de Noviembre, ISSSTE

Results:

41 patients were recruited. In both groups the most common toxicity was diarrhea in > 90% of the patients, however, grade 3-4 diarrhea in the 20 mg/m2 cabazitaxel group was 24% compared to the 25 mg/m2 group of 31.2%. A 12% of febrile neutropenia was observed in the control group compared to none patient at a dose of 20 mg/m2

Conclusions:

In our population, better tolerance of cabazitaxel at a dose of 20 mg/m2 compared to 25 mg/m2 is corroborated, we believe that the use of such dose should be a standard, as part of the tools available for the RCPC.